Maria Emilia Di Francesco

USPTO Granted Patents = 36 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 15 (Patent Applications = 14)

Average Co-Inventor Count = 6.1

ph-index = 9

Forward Citations = 246(Granted Patents)

Location History:

Pomezia, IT (2012)
Brookline, MA (US) (2013)
Rome, IT (2007 - 2015)
Houston, TX (US) (2015 - 2024)

Company Filing History:

22 out of 5,444

University of Texas System

patents

10 out of 2,405

Merck Sharp + Dohme Corp.

patents

7 out of 7

Chempartner Corporation

patents

4. 3 out of 47

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Istituto Di Ricerche Di Biologia P. Angeletti S.p.a.

patent

7. 1 out of 4

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

patents

where one patent can have more than one assignee

Years Active: 2007-2024

where 'Filed Patents' based on already Granted Patents

36 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12036231 - Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling (2024-07-16),

2. 11958849 - GLS1 inhibitors for treating disease (2024-04-16),

3. 11725008 - Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases (2023-08-15),

4. 11434233 - Heterocyclic inhibitors of ATR kinase (2022-09-06),

5. 11400108 - Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling (2022-08-02),

6. 11370786 - GLS1 inhibitors for treating disease (2022-06-28),

7. 11028083 - Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases (2021-06-08),

8. 11001594 - Heterocyclic modulators of HIF activity for treatment of disease (2021-05-11),

9. 10933078 - Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling (2021-03-02),

10. 10894052 - Heterocyclic inhibitors of ATR kinase (2021-01-19),

11. 10888554 - Salts of heterocyclic modulators of HIF activity for treatment of disease (2021-01-12),

12. 10800774 - Heterocyclic inhibitors of ATR kinase (2020-10-13),

13. 10800769 - Heterocyclic inhibitors of ATR kinase (2020-10-13),

14. 10766892 - GLS1 inhibitors for treating disease (2020-09-08),

15. 10745420 - Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase (2020-08-18),

Title: Maria Emilia Di Francesco: Innovator in Immune Response Therapies

Introduction

Maria Emilia Di Francesco, based in Houston, TX, is a renowned innovator in the field of pharmaceutical sciences with a remarkable portfolio comprising 36 patents. Her contributions span the development of novel compounds aimed at treating various medical conditions, thereby significantly impacting the landscape of medicine and immunology.

Latest Patents

Among her latest patents, one significant innovation is related to cyclic dinucleotides as agonists of stimulator of interferon gene dependent signaling. This patent discloses new cyclic dinucleotide compounds and their potential application as pharmaceuticals for treating diseases. These treatments aim to modulate immune responses against a range of conditions, including cancer, inflammation, autoimmune diseases, and infectious diseases. Another noteworthy patent focuses on GLS1 inhibitors for treating diseases mediated by GLS1, particularly in cancer therapy. This includes methods for inhibiting GLS1 activity in human or animal subjects, providing a crucial therapeutic avenue for many patients.

Career Highlights

Maria has held prominent positions in reputable organizations such as the University of Texas System and Merck Sharp & Dohme Corporation. Her work at these institutions has been instrumental in advancing research and applying innovative solutions in clinical settings. Through her expertise, she has made significant strides in developing therapies that target critical pathways in disease mechanisms.

Collaborations

Throughout her career, Maria has collaborated with esteemed colleagues such as Philip Jones and Christopher Lawrence Carroll. These partnerships have fostered a vibrant exchange of ideas and expertise, enhancing her research outcomes and enabling the successful implementation of her innovative compounds in therapeutic applications.

Conclusion

Maria Emilia Di Francesco exemplifies the spirit of innovation in the pharmaceutical industry. Her extensive patent portfolio reflects her commitment to developing groundbreaking therapies that address complex diseases. As she continues to advance her research, her contributions will undoubtedly shape the future of medical treatments and improve patient outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.